Physician profile
Phillip Bowden
NPI 1811003635
$867.54
in general payments reported to CMS, 2019-2025
10 companies · $20.48 in 2025
The $20.48 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.49 · 2020: $58.64 · 2021: $39.80 · 2022: $76.23 · 2023: $571 · 2024: $51.61 · 2025: $20.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369 · Travel and Lodging: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.30 |
| Travel and Lodging | $274.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apollo Endosurgery US INC | $494.96 | 2023 | Overstitch Endoscopic Suturing System |
| Boston Scientific Corporation | $88.66 | 2019-2025 | Resolution 360 Ultra Clip |
| Mauna Kea Technologies, INC. | $78.20 | 2023-2024 | |
| Janssen Biotech, INC. | $54.73 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.05 | 2020-2021 | |
| Pfizer INC. | $33.60 | 2023-2024 | |
| Celgene Corporation | $28.95 | 2021-2024 | Zeposia |
| Medtronic USA, INC. | $19.07 | 2020 | |
| Gilead Sciences, INC. | $16.03 | 2019 | |
| Abbvie INC. | $13.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Bowden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.